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Chlamydia trachomatis and smoking are major risk
factors for tubal ectopic pregnancy (EP), but the un-
derlying mechanisms of these associations are not
completely understood. Fallopian tube (FT) from
women with EP exhibit altered expression of proki-
neticin receptors 1 and 2 (PROKR1 and PROKR2);
smoking increases FT PROKR1, resulting in a micro-
environment predisposed to EP. We hypothesize that
C. trachomatis also predisposes to EP by altering FT
PROKR expression and have investigated this by ex-
amining NFB activation via ligation of the Toll-like
receptor (TLR) family of cell-surface pattern recogni-
tion receptors. PROKR2 mRNA was higher in FT from
women with evidence of past C. trachomatis infec-
tion than in those without (P < 0.05), and was also
increased in FT explants and in oviductal epithelial
cell line OE-E6/E7 infected with C. trachomatis (P <
0.01) or exposed to UV-killed organisms (P < 0.05).
The ability of both live and dead organisms to induce
this effect suggests ligation of a cell-surface-expressed
receptor. FT epithelium and OE-E6/E7 were both
found to express TLR2 and TLR4 by immunohisto-
chemistry. Transfection of OE-E6/E7 cells with domi-
nant-negative TLR2 or IB abrogated the C. tracho-
matis–induced PROKR2 expression. We propose that
ligation of tubal TLR2 and activation of NFBb yC. tra-
chomatis leads to increased tubal PROKR2, thereby pre-
disposing the tubal microenvironment to ectopic
implantation. (Am J Pathol 2011, 178:253–260; DOI:
10.1016/j.ajpath.2010.11.019)
Tubal ectopic pregnancy occurs in 1%–2% of all preg-
nancies in Europe and the United States.
1 In the Western
world, it remains the most common cause of maternal
mortality in the first trimester of pregnancy.
1,2
Epidemiological studies indicate that Chlamydia tra-
chomatis infection is a risk factor for tubal ectopic preg-
nancy, although there is a paucity of solid evidence for
the long-term reproductive sequelae of C. trachomatis
infection.
3,4 The extent to which C. trachomatis infection
accounts for the adhesions, tubal alteration, damage, or
occlusion that predispose to ectopic pregnancy or infer-
tility in humans remains largely unknown. However, the
mechanisms by which these occur are believed to be
primarily immunologically mediated and not a direct con-
sequence of tissue destruction by the organism,
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253though more recent evidence does support a cytotoxic
effect of C. trachomatis on ciliated epithelium.
7 C. tracho-
matis has been shown to initiate innate immune re-
sponses by ligating members of the Toll-like receptor
(TLR) family of cell-surface pattern recognition receptors,
in particular TLR2 and TLR4.
8,9 TLR ligation initiates
downstream signaling, leading to the activation of tran-
scription factors, such as NFB (nuclear factor kappa-
light-chain enhancer of activated B cells), resulting in
transcription of immune and inflammatory mediators.
10
Experimental animal models (mainly in rodent species)
of genital C. trachomatis infection provide clues to dis-
ease pathogenesis; however, these experimental infec-
tions are usually conducted using defined infectious
doses under highly controlled conditions for relatively
short periods of time, and in animals that have limited
genetic variability and with different C. trachomatis im-
mune evasion strategies compared with humans.
11–14
Using human ex vivo and in vitro models, we have
recently investigated how another risk factor for ectopic
pregnancy, cigarette smoking, leads to tubal implanta-
tion. Tubal ectopic pregnancy is thought to be a conse-
quence of embryo retention within the fallopian tube due
to impaired smooth muscle contractility and alterations
in the tubal microenvironment.
15 Our studies demon-
strate that cigarette smoking increases transcription of
prokineticin receptor 1 (PROKR1), a G-protein coupled
receptor.
16 The PROKRs are receptors for PROK1, a
molecule known for its angiogenic properties, control of
smooth muscle contractility, and regulation of genes im-
portant for intrauterine implantation.
17–19 Both PROKR1
and PROKR2 expression are altered in fallopian tube
from women with ectopic pregnancy, where implantation
has already occurred.
20
In this study, we hypothesized that, like cigarette
smoking, C. trachomatis infection alters fallopian tube
PROKR expression and thereby predisposes the tubal
microenvironment to ectopic pregnancy.
Materials and Methods
Tissue Collection
Human fallopian tube biopsies and sera were collected
from women during hysterectomy for benign gynecolog-
ical conditions (n  38). The median age of the women in
this study was 41 years (range, 27–49 years). Approval
for this study was obtained from the Lothian research
ethics committee (LREC 04/S1103/20), and informed,
written consent was obtained from each patient. Tissues
were divided into three portions and were (1) stored in
Ambion RNAlater stabilization solution (Applied Biosys-
tems, Austin, TX) overnight, after which they were frozen
at 80°C for RNA extraction, or (2) fixed in neutral-buff-
ered formalin for 24 hours and mounted in paraffin for
immunohistochemical analysis, or (3) stored fresh in PBS
for explant culture. Sera were stored frozen at 20°C until
use.
Enzyme-Linked Immunosorbent Assay for
Evidence of Past C. trachomatis Infection
Past C. trachomatis infection was determined by an en-
zyme-linked immunosorbent assay that detects serum
antibodies to PgP3 protein, as described previously.
21 A
cutoff value for absorbance at 450 nm of 0.473 gave a
specificity of 96% for identifying positive sera.
21
C. trachomatis Detection in Fallopian Tube
Biopsies by PCR
All fallopian tube biopsies included in this study were
screened for current chlamydial infection by PCR. DNA
was extracted from whole fallopian tube biopsies from the
ampullary region of the tube, as detailed in the manufac-
turers’ protocol (Qiagen, West Sussex, UK). The PCR
protocol used a well-validated, in-house, plasmid-based
methodology (kindly developed and designed by the
West of Scotland Specialist Virology Centre, Glasgow).
RNA Extraction, cDNA Preparation, and
Quantitative Real-Time PCR
RNA was extracted from fallopian tube tissue using
TRIzol reagent (Invitrogen, Paisley, UK) according to the
manufacturer’s recommended method. After extraction,
RNA was treated with DNase and was purified using
RNeasy (Qiagen, West Sussex, UK). RNA was extracted
from cells using the Qiagen RNeasy kit, which included a
DNase treatment step. RNA concentrations were quanti-
fied using a NanoDrop spectrophotometer (Thermo
Fisher Scientific, Wilmington, DE). Two hundred nano-
grams of RNA was reverse-transcribed into cDNA using
random hexamers, according to the recommended
method (Applied Biosystems [ABI], Foster City, CA). Taq-
Man real-time PCR was used to quantify PROKR mRNA
transcript levels. Reactions were performed using an ABI
Prism 7900 system, using standard conditions. Previ-
ously validated primer and FAM (6-carboxyfluorescein)
labeled probe sequences are listed in Table 1. All reac-
tions were performed in triplicate. Gene expression was
normalized to RNA loading using primers and VIC la-
beled probe (Applied Biosystems) for ribosomal 18S as
an internal standard and expressed as relative to a pos-
Table 1. qRT-PCR Primer and Probe Sequences
Primer/probe
(label) Sequence
PROKR1 forward 5=-TCTTACAATGGCGGTAAGTCCA-=3
PROKR1 reverse 5=-CTCTTCGGTGGCAGGCAT-=3
PROKR1 probe
(FAM)
5=-TGCAGACCTGGACCTCAAGACAAT-
TGG-=3
PROKR2 forward 5=-GCTCTGTGCCTCCGTCAACT-=3
PROKR2 reverse 5=-CCAGCAAGGCATTGGTGG-=3
PROKR2 probe
(FAM)
5=-CCTGCGCACCGTCTCCCTCTACG-=3
18S forward 5=-CGGCTACCACATCCAAGGAA-=3
18S reverse 5=-GCTGGAATTACCGCGGCT-=3
18S probe (VIC) 5=-TGCTGGCACCAGACTTGCCCTC-=3
254 Shaw et al
AJP January 2011, Vol. 178, No. 1itive RNA standard (cDNA from a single mid-secretory
endometrial tissue) that was included in all reactions.
Immunohistochemistry for TLR2 and TLR4
Standard immunohistochemistry procedures were used
to localize TLR2 and TLR4 in fallopian tube tissue, as
described previously.
20 A TLR2-specific goat polyclonal
antibody (Abcam, Cambridge, UK) was diluted 1:250 in
normal horse serum and a TLR4-specific rabbit poly-
clonal antibody (Abcam) was diluted 1:100 in normal
goat serum. Normal goat IgG and rabbit IgG diluted in
the same way as the primary antibodies were used as
negative controls for TLR2 and TLR4 staining, respec-
tively.
For immunocytochemistry, cells of oviductal epithelial
cell line OE-E6/E7 were seeded at 500,000 cells/chamber
on BD Falcon chamber slides (BD Biosciences, Oxford,
UK) in Dulbecco’s modified Eagle’s medium/Ham’s F12
(DMEM/F12) (Invitrogen) and incubated overnight at
37°C, 5% CO2. Medium was then removed and adherent
cells fixed in 90% acetone, 10% methanol. Fixed cells
were blocked in 3% hydrogen peroxide in methanol for
30 minutes, then washed twice in phosphate-buffered
saline (PBS). Avidin and biotin blocks were then per-
formed (Vector Laboratories, Peterborough, UK) accord-
ing to the manufacturer’s recommended method. Cells
were then washed and blocked in antibody diluent (nor-
mal horse serum for TLR2 and normal goat serum for
TLR4) for 30 minutes. TLR2 goat polyclonal antibody
(Abcam) was diluted 100-fold in antibody diluent for im-
munocytochemistry; TLR4 rabbit polyclonal antibody
(Abcam) was diluted 100-fold. Immunocytochemistry
was completed as described above for immunohisto-
chemistry.
Oviductal Epithelial OE-E6/E7 Cell Culture
Oviductal epithelial OE-E6/E7 cells
22 were maintained in
DMEM/F12 containing 10% fetal bovine serum at 37°C,
5% CO2. For experiments, cells were seeded at 500,000
cells per well of a 12-well dish (BD Biosciences) and
cultured for 24 hours, after which the medium was then
removed, the cells were washed once with PBS and
serum-free DMEM/F12 was added, and the cells were
incubated overnight. Cells were exposed either to C.
trachomatis (serovar E) as previously described
23 or to
synthetic TLR ligands, as described below. C. trachoma-
tis exposures included UV-killed C. trachomatis (multiplic-
ity of infection [MOI] 1.0) or live C. trachomatis at MOI
values of 0.1 and 1.0 (all diluted in serum-free DMEM/
F12). Synthetic ligands were triacetylated lipoprotein
(Pam3 CSK4; 100 ng/ml) for TLR2 or monophosphoryl
lipid A (MPLA; 100 ng/ml) for TLR4 (InvivoGen, San Di-
ego, CA). Control cells were cultured in medium alone.
Cells were treated for 8, 12, 24, or 48 hours, after which
the medium was removed and the cells were treated with
Qiagen RLT buffer, then frozen at 80°C before RNA
extraction.
Fallopian Tube Explant Culture
Fallopian tube biopsies were cultured as described pre-
viously.
20 Tissues were exposed to C. trachomatis,a s
described above. After treatment, tissues were treated
with TRIzol reagent (Invitrogen) and frozen at 80°C
before RNA extraction.
Transient Transfection of OE-E6/E7 Cells with
Dominant Negative TLR2
Cells were transiently transfected by electroporation with
empty p-zero plasmid (control) or p-zero plasmid con-
taining a dominant negative form of TLR2 in which the
conserved Toll-like TIR domain has been removed, ren-
dering TLR2 unable to signal downstream (InvivoGen,
Toulouse, France). For electroporation, 400 L of cells at
a concentration of 2.2  10
6 cells/ml in DMEM/F12 
10% fetal bovine serum were added to each 0.4-cm
cuvette (Bio-Rad, Hemel Hempstead, UK) on ice, and 20
g of plasmid in a volume of 40 L was added to the cells
in each cuvette. Cells were electroporated using a Bio-
Rad Gene Pulser system at a voltage of 0.26 kV with
infinite internal resistance and maximum capacitance.
After electroporation, 200 L of cells were added to 1 ml
of DMEM/F12  10% fetal bovine serum in a 12-well dish.
Cells were incubated for 48 hours at 37°C, 5% CO2. The
medium was then replaced with serum-free DMEM/F12
overnight before cells were treated with C. trachomatis or
TLR2 ligand, as described above. After treatments, cells
were treated with Qiagen RLT buffer and frozen at 80°C
before RNA extraction.
Transformation of OE-E6/E7 Cells with
Dominant Negative IB
Cells were seeded at 2.5  10
5 cells/ml in a 12-well dish
and were cultured for 24 hours at 37°C, 5% CO2. Medium
was then removed and replaced with serum-free DMEM/
F12, and the cells were cultured overnight. Cells were
then treated with either control adenovirus (Ad-d1703) or
the same virus but containing a dominant negative IB
mutant, as described previously.
24,25 Adenovirus was
used at an MOI of 100 and the cells were cultured for 24
hours, after which they were treated with either C. tracho-
matis or with synthetic TLR2 ligand, as described above.
After these treatments, cells were treated with Qiagen
RLT buffer and were frozen at 80°C before RNA extrac-
tion.
Statistical Analysis
All statistical analyses were performed using GraphPad
Prism software (version 4.02; La Jolla, CA). Differences
between groups were analyzed using two-tailed, un-
paired t-tests and differences were considered signifi-
cant when P  0.05.
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PROKR2 mRNA Levels Are Increased in
Fallopian Tube from Women with Evidence of
Past C. trachomatis Infection
Study participants were divided into two groups on the
basis of the 0.473 cutoff for absorbance at 450 nm.
Fourteen of the women in this study were identified as
seropositive for past C. trachomatis infection (mean ab-
sorbance, 1.133). The remaining 24 women were identi-
fied as seronegative for past infection (mean absor-
bance, 0.084). The levels of mRNA encoding PROK1,
PROK2, PROKR1, and PROKR2 were measured in fallo-
pian tube from patients using quantitative real-time PCR.
There were no differences in PROK1 or PROK2 levels in
fallopian tube from women with evidence of past C. tra-
chomatis infection, compared with women with no evi-
dence of past infection (data not shown). In one patient
sample, PROKR1 levels were undetermined; in the re-
maining samples, PROKR1 levels were no different be-
tween women with and without evidence of past C. tra-
chomatis infection (Figure 1A). PROKR2 levels, however,
were significantly higher in fallopian tube from women
with evidence of past C. trachomatis infection, compared
with women with no evidence of past infection (Figure 1B,
P  0.05). All fallopian tube biopsies were screened for
current C. trachomatis infection by PCR and were shown
to be negative (data not shown). In addition, all fallopian
tube samples were routinely examined under hematoxy-
lin and eosin staining by a gynecological histopatholo-
gist. None of the samples showed microscopic evidence
of chronic inflammation.
Oviductal Epithelial OE-E6/E7 Cell and Fallopian
Tube Expression of PROKR2 mRNA Is
Increased with Exposure to C. trachomatis
There were no changes in PROKR1 mRNA expression in
OE-E6/E7 cells or fallopian tube explants treated with C.
trachomatis (data not shown). However, PROKR2 mRNA
expression levels were significantly increased after 8
hours in OE-E6/E7 cells (Figure 2)( n  5). To confirm that
the increases seen with the UV-treated C. trachomatis
were not due to surviving organisms infecting the cells,
we tested the infectious ability of the live and UV-inacti-
vated C. trachomatis using the OE-E6/E7 cell line. We
infected the cells with various levels of C. trachomatis for
varying lengths of time, from 8 hours to a maximum of 48
hours. By 48 hours, we demonstrated infection of OE-
E6/E7 cells by live C. trachomatis, evidenced by the for-
mation of inclusion bodies when cells were fixed and
stained with a C. trachomatis--specific lipopolysaccha-
ride antibody (infectivity of approximately 24%; see Sup-
plemental Figure S1A at, http://ajp.amjpathol.org). No in-
fection of cells was demonstrated by the same
concentration of UV-killed C. trachomatis even after 48
Figure 1. PROKR1 and PROKR2 mRNA levels in women with and without
serological evidence of past C. trachomatis infection. Anti-PgP antibodies in
patient sera were measured by enzyme-linked immunosorbent assay as
evidence of past C. trachomatis infection. Patients were divided into two
groups, negative (n  24) and positive (n  14), based on a predetermined
cutoff value. Quantitative real-time PCR (qRT-PCR) was used to measure
PROKR1 (A) and PROKR2 (B) transcript levels in fallopian tube from patients
in these two groups, as described under Materials and Methods.
*P  0.05. Error bars indicate the SEM.
Figure 2. PROKR2 mRNA levels in OE-E6/E7 cells and fallopian tube ex-
plants treated with C. trachomatis in vitro. A: OE-E6/E7 cells (n  5) were
infected with C. trachomatis (MOI 1.0) or exposed to UV-killed organisms
(MOI 1.0 equivalent), for 8 hours. qRT-PCR was used to measure PROKR2
mRNA levels in the treated cells. B: Fallopian tube explants (n  4) were
infected with C. trachomatis (MOI 0.1 and 1.0) or exposed to UV-killed
organisms (MOI 1.0 equivalent), and PROKR2 mRNA levels were measured
using qRT-PCR. Error bars indicate the SEM. *P  0.05; **P  0.01.
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S1B at, http://ajp.amjpathol.org).
TLR2 and TLR4 Localize to the Epithelium in
Human Fallopian Tube and Are Expressed in
Oviductal Epithelial OE-E6/E7 Cells
Both TLR2 and TLR4 were found to be expressed in the
fallopian tube epithelium by immunohistochemistry (Fig-
ure 3, A and B). In OE-E6/E7 cells, TLR2 was shown to be
expressed by immunocytochemistry (Figure 3C), but we
could not identify any TLR4 staining (Figure 3D). We have
no explanation for the discrepancy between the tissue
and OE-E6/7 cell-line expression of TLR4, other than to
say that alterations in gene expression can occur in vitro
during the immortalization of cells. In addition, changes in
the expression of certain proteins may also be the result
of long-term culture conditions associated with the use of
immortalized cell lines.
PROKR2 mRNA Expression in OE-E6/E7 Cells
Can Be Induced by TLR2 Activation
Promoter analysis of prokineticin genes has highlighted
that they can be activated by TLR signaling.
26 Hence, we
investigated the effect of treatment with TLR ligands on
PROKR2 expression. PROKR2 levels were significantly
increased in OE-E6/E7 cells treated with TLR2 ligand
(Figure 4A; P  0.01). In contrast, PROKR2 levels were
not altered in cells treated with a synthetic ligand for TLR4
(Figure 4B). Given this finding, the absence of accessory
molecules necessary for TLR4 activation in the OE-E6/E7
cells, such as MD2 and CD14, cannot be ruled out. The
lack of response to TLR4 ligand may also be due to the
lack of TLR4 protein expression identified in OE-E6/E7
cells by immunocytochemistry (Figure 3D).
To confirm that the increase in PROKR2 expression
observed in OE-E6/E7 cells in response to treatment with
a TLR2 ligand was mediated through TLR2, cells were
transiently transfected with either a control plasmid or a
plasmid containing a dominant negative form of TLR2.
Transfection of OE-E6/E7 cells with dominant negative
TLR2 prevented the increase in PROKR2 expression after
treatment with the ligand. No effect was observed in cells
transfected with the empty plasmid (Figure 4B). These
results confirm that PROKR2 expression can be in-
creased in response to TLR2 ligation in OE-E6/E7 cells.
As for the treatment with synthetic TLR ligand, transient
expression of the dominant negative TLR2 negated the
increase in PROKR2 mRNA expression induced by C.
trachomatis infection or by exposure to UV-killed organ-
isms, confirming that C. trachomatis induces PROKR2
expression through activation of TLR2 (Figure 5).
C. trachomatis-Induced PROKR2 mRNA
Expression in OE-E6/E7 Cells Is Partially
Mediated by NFB Activation
OE-E6/E7 cells were transformed with adenovirus contain-
ing an empty vector or containing a dominant negative form
of IB with point mutations at two serine residues required
for its phosphorylation. After transformation with adenovi-
rus for 24 hours, cells were infected with C. trachomatis or
exposed to UV-killed organisms for 8 hours (n  3). The
increase in PROKR2 mRNA expression induced by either
Figure 3. Immunohistochemical localization of TLR2 and TLR4 in fallopian
tube tissue and OE-E6/E7 cells. Immunohistochemical staining for TLR2 and
TLR4 in human fallopian tube explants and in OE-E6/E7 cells, as described
under Materials and Methods. TLR2 (A, C) and TLR4 (B, D). Inset: Negative
control, for each primary stain. Magnification, X40.
Figure 4. PROKR2 mRNA levels in OE-E6/E7 cells treated with synthetic
TLR2 and TLR4 ligands and in cells transfected with dominant negative TLR2.
A: OE-E6/E7 cells (n  3) were treated with a TLR2 ligand (Pam3 CSK4, 100
ng/ml) and a TLR4 ligand (MPLA, 100 ng/ml) for 8 hours. PROKR2 mRNA
levels were measured using qRT-PCR, as described under Materials and
Methods. B: OE-E6/E7 cells were transiently transfected with a dominant-
negative TLR2 construct using electroporation. Transfected cells were treated
with synthetic TLR2 ligand for 8 hours and PROKR2 mRNA levels were
measured by qRT-PCR. Error bars indicate the SEM. *P  0.05; **P  0.01.
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transformed with dominant negative IB (Figure 6), in-
dicating that NFB activates transcription of PROKR2 in
response to C. trachomatis infection of OE-E6/E7 cells
(although levels of PROKR2 were lower than those re-
ported in Figure 2).
Discussion
Here we present a mechanism that may explain the ep-
idemiological link between C. trachomatis infection and
tubal ectopic pregnancy. Alterations in PROK signaling
have been previously shown to promote a microenviron-
ment conducive to embryo implantation.
20,27,28 We pro-
pose that C. trachomatis infection increases tubal expres-
sion of PROKR2 mRNA, thus predisposing to ectopic
implantation in the fallopian tube, and that this effect is
mediated by TLR2 and NFB.
To support this hypothesis, we report that expression
levels of PROKR2 mRNA are higher in fallopian tube from
women with serological evidence of past C. trachomatis
infection, compared with women with no serological evi-
dence of past infection. In addition, we demonstrate that
exposure of fallopian tube explants and an oviductal epi-
thelial cell line (OE-E6/E7) to C. trachomatis in vitro causes
an upregulation of PROKR2 mRNA expression. We show
that this effect is rapid (within 8 hours) and is seen also with
UV-killed C. trachomatis, suggesting involvement of a pat-
tern recognition receptor. We demonstrate that the pattern
recognition receptor TLR2 is expressed in the fallopian tube
epithelium and that PROKR2 mRNA levels are increased in
OE-E6/E7 cells treated with a synthetic TLR2 ligand. We
also show that transient expression of a dominant negative
TLR2 by OE-E6/E7 cells reduces the induction of PROKR2
expression caused by TLR2 ligand or C. trachomatis treat-
ment. Finally, we demonstrate that transformation of OE-
E6/E7 cells with an adenovirus expressing the inhibitor pro-
tein IB (a dominant negative inhibitor of NFB) partially
negates the induction of PROKR2 expression resulting from
TLR2 ligand or C. trachomatis treatment. This suggests that
activation of TLR2 signaling by C. trachomatis results in the
activation of NFB, which is partially responsible for induc-
tion of PROKR2 transcription in the fallopian tube.
Our data suggest that TLR2 ligation by C. trachomatis in
the human fallopian tube is an important feature of the early
host immune response to infection, comparable to results
from studies in mice.
29,30 Macrophages and fibroblasts
from homozygous TLR2 knockout mice have been found to
produce less inflammatory cytokines than heterozygous
TLR2 knockouts in response to C. trachomatis infection.
31
Similar results were also reported in in vitro studies where
mouse dendritic cells and macrophages were infected with
C. pneumoniae.
29,30 Furthermore, oviducts of homozygous
TLR2 knockout mice showed no evidence of chronic inflam-
matory responses after C. trachomatis infection was re-
solved, compared with mice expressing wild-type TLR2.
31
These results, in addition to our findings in human fallopian
tube, suggest that TLR2 may be responsible for initiating the
long-term immunological responses associated with C. tra-
chomatis infection.
TLR2 ligation by C. trachomatis can occur on the cell
surface as well as intracellularly, where TLR2 recruitment
to C. trachomatis inclusion bodies has been reported.
9
Our data demonstrating activation of TLR2 signaling by
both live and UV-killed C. trachomatis suggests cell sur-
face ligation and does not rule out intracellular ligation in
oviductal epithelial cells. The precise components of C.
trachomatis that ligate TLR2 in OE-E6/E7 cells are un-
known. Previous studies have demonstrated activation of
TLR2 by both endogenous heat-shock protein 60
(HSP60)
32 and HSP60 produced by C. pneumoniae.
33
Results from the current study allow us to speculate that
HSP60 from C. trachomatis may also activate TLR2 sig-
naling.
We also demonstrate novel regulation of PROKR2 mRNA
expression either directly or indirectly by NFB. Regulation
of PROK and PROKR expression has not been studied
extensively. However, these genes have been shown to be
hormonally regulated in the endometrium (PROK1) and fal-
lopian tube (PROK2, PROKR1)
34,20; regulated by hypoxia
in human trophoblast (PROK1 and PROKR1)
35; and reg-
ulated by cytokines, such as granulocyte colony-stimula-
tory factor and granulocyte-macrophage colony-stimula-
tory factor, in human immune cells (PROK2).
36
Regulation by NFB is relevant in ectopic pregnancy,
because NFB signaling plays a central role in controlling
Figure 5. PROKR2 mRNA levels in OE-E6/E7 cells transiently expressing
dominant-negative TLR2 and treated with C. trachomatis. OE-E6/E7 cells
(n  4) were transiently transfected with a dominant-negative form of TLR2
using electroporation. Cells were infected with C. trachomatis (MOI 1.0) or
exposed to UV-killed organisms for 8 hours and PROKR2 levels were mea-
sured by qRT-PCR, as described under Materials and Methods. Error bars
indicate the SEM. *P  0.05; **P  0.01.
Figure 6. PROKR2 mRNA levels in OE-E6/E7 cells transformed with Ade-
novirus expressing dominant negative IB and exposed to C. trachomatis.
OE-E6/E7 cells (n  3) were transformed with a control adenovirus or
adenovirus expressing a dominant-negative form of the NFB inhibitor,
IB. Cells were infected with C. trachomatis (MOI 1.0) or exposed to
UV-killed organisms (MOI 1.0 equivalent) and PROKR2 mRNA levels were
measured by qRT-PCR, as described under Materials and Methods. Error bars
indicate the SEM. ***P  0.001; **P  0.01; *P  0.05.
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tant for activating immune responses, such as cytokines,
chemokines, and adhesion molecules; in the endome-
trium, expression of active NFB components, such as
p65 and p50, has been shown to be increased during the
window of implantation.
37–39
We believe that our findings not only are important in
the context of ectopic pregnancy but may have wider
implications in helping to explain the association of C.
trachomatis with other pathologies. C. trachomatis in-
fection is also associated with pelvic inflammatory dis-
ease
40 and ocular trachoma.
41 Pelvic inflammatory dis-
ease is thought to be caused by C. trachomatis in 20%
to 40% of cases and accounts for 18% of cases of
infertility
42 and 5% of cases of chronic pelvic pain.
43
These statistics have led to the introduction of a na-
tional C. trachomatis screening program in England
(http://www.chlamydiascreening.nhs.uk). Ocular tra-
choma, caused by C. trachomatis infection of the con-
junctival epithelium, has blinded 1 million people in
the developing world.
44 The most recent estimate from
the World Health Organization placed the burden of
disease at approximately 1.3 million disability-adjusted
life-years.
41 Thus, further understanding of the effects
of C. trachomatis on epithelial cell function, inflamma-
tion, and the microenvironment should lead to improve-
ments in disease control.
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